Isolation of alpha1 -fetoprotein

Claim 2

A process for producing purified alpha 1 -fetoprotein comprising: (a) buffering a sample of a biological source material known to contain alpha 1 -fetoprotein to a pH of about 7; (b) subjecting said buffered sample to affinity chromatography by passage through a column containing an antibody specific for alpha 1 -fetoprotein immobilized on a solid support and subseqently eluting the bound alpha 1 -fetoprotein by treatment of the column with a suitable desorbing agent; (c) removing substantially all of the albumin present in the eluate from step (b) by subjecting it to adsorption chromatography by passage through a column containing an immobilized reactive dye adsorbent; (d) dialyzing the unadsorbed alpha 1 -fetoprotein-containing solution from step (c); (e) lyophilizing the dialyzed solution from step (d); (f) dissolving the powder formed in step (e) in a suitable buffer and subjecting eh resulting solution to polyacrylamide gel electrophoresis.

Claim 3

The process according to claim 1 wherein said source material is monkey hepatoma serum.

Claim 4

The process according to claim 1 wherein the alpha 1 -fetoprotein content of the sample is monitored by immunoassay after said steps (b), (c) and (f).

Claim 5

The process according to claim 1 wherein said desorbing agent is selected from the group consisting of: aqueous solutions of urea having a urea concentration of from about 6 to about 8 molar; aqueous solutions of sodium chloride having a sodium concentration of not less than about 0.5 molar; buffers having a pH of from about 2 to about 3 and buffers containing a chaotropic ion.

Claim 6

The process in accordance with claim 4 wherein said desorbing agent is a buffer containing a chaotropic ion, said buffer being a 0.1 M sodium phosphate buffer at about pH 7.0 and said chaotropic ion being the thiocyanate ion.

Claim 7

The process according to claim 1 wherein said solid support for said alpha 1 -fetoprotein specific antibody is selected from the group consisting of agarose gels, porous glass beads and polyacrylamide beads.

Claim 8

The process according to claim 1 wherein said buffer in step (f) comprises an aqueous solution containing about 0.6% by weight 2-amino-2-(hydroxymethyl)-1,3-propanediol and about 3.0% glycine having a pH of about 8.3.

Claim 9

The process in accordance with claim 1 wherein said polyacrylamide gel electrophoresis comprises passage of said sample sequentially through a large pore polyacrylamide concentrating gel and a small pore polyacrylamide resolving gel over about 24 hours under a constant current of about 40 mA.

Claim 10

The process in accordance with claim 8 wherein the alpha 1 -fetoprotein is recovered by eluting portions of said resolving gel with 0.05 M borate buffer at pH 8.4 and concentrating the eluates by ultrafiltration.

Claim 11

The process in accordance with claim 1 wherein said reactive dye is a sulfonated, polyaromatic dye containing a 1, 3, 5-triazine nucleus and a single reactive chlorine.

Claim 12

The process according to claim 10 wherein said reactive dye has the structure ##STR2##

Claim 13

The process according to claims 1, 10 or 11 wherein said immobilized reactive dye adsorbent comprises an agarose gel covalently linked to dextran having bound thereto a dye having the structure ##STR3##

Claim 14

A process for producing purified alpha 1 -fetoprotein comprising: (a) buffering a sample of a biological source material known to contain alpha 1 -fetoprotein to a pH of about 7; (b) subjecting said buffered sample to affinity chromatography by passage through a column containing an antibody specific for alpha 1 -fetoprotein immobilized on a solid support and subsequently eluting the bound alpha 1 -fetoprotein by treatment of the column with a suitable desorbing agent; (c) removing substantially all of the albumin present in the eluate from step (b) by subjecting it to adsorption chromatography by passage through a column containing an immobilized reactive dye adsorbent; (d) dialyzing the unadsorbed alpha 1 -fetoprotein-containing soution from step (c); (e) removing high molecular weight protein contaminants from the dialyzed olution from step (d) by subjecting it to gel filtration chromatography utilizing as the filtering material a hydrophilic, water-insoluble, cross-linked dextran polymer gel; (f) treating the eluate containing alpha 1 -fetoprotein from step (e) to remove protein contaminants by subjecting it to ion exchange chromatography utilizing as the filtering material a mixture of a cationic exchange resin and an anionic exchange resin; (g) dialyzing the eluate containing alpha 1 -fetoprotein from step (f); (h) lyophilizing the dialyzed solution from step (g); (i) dissolving the powder formed in step (h) in a suitable buffer and subjecting the resulting solution to polyacrylamide gel electrophoresis.

Claim 15

A process for producing purified alpha 1 -fetoprotein comprising: (a) buffering a sample of a biological source material known to contain alpha 1 -fetoprotein to a pH of about 7; (b) subjecting said buffered sample to affinity chromatography by passage through a column containing an antibody specific for alpha 1 -fetoprotein immobilized on a solid support and subsequently eluting the bound alpha 1 -fetoprotein by treatment of the column with a suitable desorbing agent; (c) removing substantially all of the albumin present in the eluate from step (b) by subjecting it to adsorption chromatography by passage through a column containing an immobilized reactive dye adsorbent; (d) dialyzing the unadsorbed alpha 1 -fetoprotein-containing soution from step (c); (e) removing high molecular weight protein contaminants from the dialyzed olution from step (d) by subjecting it to gel filtration chromatography utilizing as the filtering material a hydrophilic, water-insoluble, cross-linked dextran polymer gel; (f) treating the eluate containing alpha 1 -fetoprotein from step (e) to remove protein contaminants by subjecting it to ion exchange chromatography utilizing as the filtering material a mixture of a cationic exchange resin and an anionic exchange resin; (g) dialyzing the eluate containing alpha 1 -fetoprotein from step (f); (h) lyophilizing the dialyzed solution from step (g); (i) dissolving the powder formed in step (h) in a suitable buffer and subjecting the resulting solution to polyacrylamide gel electrophoresis.

Claim 16

The process according to claim 10 wherein said source material is cord blood or cord serum.

Claim 17

The process according to claim 10 wherein the alpha 1 -fetoprotein content of the samples is monitored by immunoassay after said steps (b), (c), (e), (f) and (i).

Claim 18

The process according to claim 10 wherein said buffer in step (d) is a 0.05 M sodium phosphate buffer containing 0.15 M sodium chloride and 0.02% by weight sodium azide.

Claim 19

The process according to claim 10 wherein said desorbing agent is selected from the group consisting of: aqueous solutions of urea having a urea concentration of from about 6 to about 8 molar; aqueous solutions of sodium chloride having a sodium concentration of not less than about 0.5 molar; buffers having a pH of from about 2 to about 3 and buffers containing a chaotropic ion.

Claim 20

The process in accordance with claim 14 wherein said desorbing agent is a buffer containing a chaotropic ion, said buffer being a 0.1 M sodium phosphate buffer at about pH 7.0 and said chaotropic ion being the thiocyanate ion.

Claim 21

The process according to claim 10 wherein said solid support for said alpha 1 -fetoprotein specific antibody is selected from the group consisting of agarose gels, porous glass beads and polyacrylamide beads.

Claim 22

The process according to claim 10 wherein in step (d) the solution is dialyzed against the buffer utilized in step (a).

Claim 23

The process according to claim 10 wherein said cross-linked dextran polymer gel utilized in step (e) has a molecular exclusion of about 200,000, a water regain of 20±2.0 g. water/g. dry gel and a particle size of 40-120 microns.

Claim 24

The process according to claim 10 wherein said cationic exchange resin utilized in step (f) is carboxymethyl cellulose and said anionic exchange resin is diethylaminoethyl cellulose.

Claim 25

The process in accordance with claim 19 wherein the alpha 1 -fetoprotein solution obtained from step (e) are dialyzed against a 0.1 M ammonium acetate buffer, pH about 6.25 being applied to the column in step (f) and, after said column has been washed with said buffer, the alpha 1 -fetoprotein is eluted therefrom by treating the column with an increasing gradient of sodium chloride in said buffer.

Claim 26

The process according to claim 10 wherein said buffer in step (i) comprises an aqueous solution containing about 0.6% by weight 2-amino-2-(hydroxymethyl)-1,3-propanediol and about 3.0% glycine having a pH of about 8.3.

Claim 27

The process in accordance with claim 10 wherein said polyacrylamide electrophoresis comprises passage of said sample sequentially through a large pore polyacrylamide concentrating gel and a small pore polyacrylamide resolving gel over 24 hours under a constant current of about 40 mA.

Claim 28

The process in accordance with claim 22 wherein the alpha 1 -fetoprotein is recovered by eluting portions of said resolving gel with 0.05 M borate buffer at pH 8.4 and concentrating the eluates by ultrafiltration.

Claim 29

The process in accordance with claim 13 wherein said reactive dye is a sulfonated, polyaromatic dye containing a 1, 3, 5-triazine nucleus and a single reactive chlorine.

Claim 30

The process according to claim 27 wherein said reactive dye has the structure ##STR4##

Claim 31

The process according to claims 13, 27 or 28 wherein said immobilized reactive dye adsorbent comprises an agarose gel covalently linked to dextran having bound thereto a dye having the structure ##STR5##

Claim 32

Radioiodinated alpha 1 -fetoprotein suitable for use in a human radioimmuno-assay comprising alpha 1 -fetoprotein purified from monkey source material in accordance with the method of claim 1 and radiolabeled with iodine 125.

Claim 33

Radioiodinated alpha 1 -fetoprotein inaccordance with claim 24 wherein said monkey source material is monkey hepatoma serum.

Claim 34

In a radioimmunoassay for the alpha 1 -fetoprotein in an unknown comprising: (a) forming a complex of the alpha 1 -fetoprotein in the unknown with an antiserum; (b) adding thereto radiolabeled alpha 1 -fetoprotein; (c) removing the resulting complex from solution; and (d) measuring the amount of radiolabeled alpha 1 -fetoprotein taken up against a standard the improvement which comprises utilizing as said radiolabeled alpha 1 -fetoprotein purified according to the process of claim 10.

Claim 35

In a radioimmunoassay for the alpha 1 -fetoprotein in an unknown comprising: (a) forming a complex of the alpha 1 -fetoprotein in the unknown with antiserum; (b) adding thereto radiolabeled alpha 1 -fetoprotein; (c) removing the resulting complex from solution; and (d) measuring the amount of radiolabeled alpha 1 -fetoprotein taken up against a standard the improvement which comprises utilizing as said radiolabeled alpha 1 -fetoprotein purified from monkey source material according to the method of claim 1.

Claim 36

The improved radioimmunoassay according to claim 27 wherein said monkey source material is monkey hepatoma serum.